Story thread · 2 reports / 2 sources
BoomRay and Novartis Pharma sign $900m deal for radioligand therapy
finance.yahoo.com · 18h
First report: BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset — buffalonews.com, 2d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.